+
データを開く
-
基本情報
| 登録情報 | データベース: PDB / ID: 5vq2 | ||||||
|---|---|---|---|---|---|---|---|
| タイトル | Crystal structure of human WT-KRAS in complex with GTP | ||||||
要素 | GTPase KRas | ||||||
キーワード | HYDROLASE | ||||||
| 機能・相同性 | 機能・相同性情報response to mineralocorticoid / GMP binding / forebrain astrocyte development / LRR domain binding / regulation of synaptic transmission, GABAergic / negative regulation of epithelial cell differentiation / response to isolation stress / response to gravity / epithelial tube branching involved in lung morphogenesis / type I pneumocyte differentiation ...response to mineralocorticoid / GMP binding / forebrain astrocyte development / LRR domain binding / regulation of synaptic transmission, GABAergic / negative regulation of epithelial cell differentiation / response to isolation stress / response to gravity / epithelial tube branching involved in lung morphogenesis / type I pneumocyte differentiation / Rac protein signal transduction / positive regulation of Rac protein signal transduction / Signaling by RAS GAP mutants / Signaling by RAS GTPase mutants / Activation of RAS in B cells / myoblast proliferation / RAS signaling downstream of NF1 loss-of-function variants / skeletal muscle cell differentiation / RUNX3 regulates p14-ARF / positive regulation of glial cell proliferation / SOS-mediated signalling / Activated NTRK3 signals through RAS / Activated NTRK2 signals through RAS / SHC1 events in ERBB4 signaling / cardiac muscle cell proliferation / Signalling to RAS / Activated NTRK2 signals through FRS2 and FRS3 / SHC-related events triggered by IGF1R / Estrogen-stimulated signaling through PRKCZ / glial cell proliferation / SHC-mediated cascade:FGFR3 / MET activates RAS signaling / SHC-mediated cascade:FGFR2 / Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants / Signaling by PDGFRA extracellular domain mutants / SHC-mediated cascade:FGFR4 / PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases / Erythropoietin activates RAS / SHC-mediated cascade:FGFR1 / Signaling by FGFR4 in disease / FRS-mediated FGFR3 signaling / Signaling by CSF3 (G-CSF) / Signaling by FLT3 ITD and TKD mutants / FRS-mediated FGFR2 signaling / FRS-mediated FGFR4 signaling / FRS-mediated FGFR1 signaling / p38MAPK events / Signaling by FGFR3 in disease / protein-membrane adaptor activity / Tie2 Signaling / striated muscle cell differentiation / Signaling by FGFR2 in disease / GRB2 events in EGFR signaling / SHC1 events in EGFR signaling / Signaling by FLT3 fusion proteins / FLT3 Signaling / Signaling by FGFR1 in disease / EGFR Transactivation by Gastrin / NCAM signaling for neurite out-growth / CD209 (DC-SIGN) signaling / Downstream signal transduction / GRB2 events in ERBB2 signaling / homeostasis of number of cells within a tissue / Insulin receptor signalling cascade / Ras activation upon Ca2+ influx through NMDA receptor / SHC1 events in ERBB2 signaling / response to glucocorticoid / Constitutive Signaling by Overexpressed ERBB2 / Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants / VEGFR2 mediated cell proliferation / small monomeric GTPase / FCERI mediated MAPK activation / liver development / RAF activation / Signaling by ERBB2 TMD/JMD mutants / female pregnancy / Signaling by SCF-KIT / Constitutive Signaling by EGFRvIII / Signaling by high-kinase activity BRAF mutants / regulation of long-term neuronal synaptic plasticity / MAP2K and MAPK activation / Signaling by ERBB2 ECD mutants / visual learning / Signaling by ERBB2 KD Mutants / cytoplasmic side of plasma membrane / cytokine-mediated signaling pathway / Signaling by CSF1 (M-CSF) in myeloid cells / Regulation of RAS by GAPs / RAS processing / Negative regulation of MAPK pathway / Signaling by RAF1 mutants / Signaling by moderate kinase activity BRAF mutants / Paradoxical activation of RAF signaling by kinase inactive BRAF / Signaling downstream of RAS mutants / GDP binding / Signaling by BRAF and RAF1 fusions / positive regulation of cellular senescence / DAP12 signaling / MAPK cascade / Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 類似検索 - 分子機能 | ||||||
| 生物種 | Homo sapiens (ヒト) | ||||||
| 手法 | X線回折 / シンクロトロン / 分子置換 / 解像度: 1.96 Å | ||||||
データ登録者 | Xu, S. / Long, B. / Boris, G. / Ni, S. / Kennedy, M.A. | ||||||
引用 | ジャーナル: Acta Crystallogr D Struct Biol / 年: 2017タイトル: Structural insight into the rearrangement of the switch I region in GTP-bound G12A K-Ras. 著者: Xu, S. / Long, B.N. / Boris, G.H. / Chen, A. / Ni, S. / Kennedy, M.A. | ||||||
| 履歴 |
|
-
構造の表示
| 構造ビューア | 分子: Molmil Jmol/JSmol |
|---|
-
ダウンロードとリンク
-
ダウンロード
| PDBx/mmCIF形式 | 5vq2.cif.gz | 83.2 KB | 表示 | PDBx/mmCIF形式 |
|---|---|---|---|---|
| PDB形式 | pdb5vq2.ent.gz | 61.9 KB | 表示 | PDB形式 |
| PDBx/mmJSON形式 | 5vq2.json.gz | ツリー表示 | PDBx/mmJSON形式 | |
| その他 | その他のダウンロード |
-検証レポート
| 文書・要旨 | 5vq2_validation.pdf.gz | 1 MB | 表示 | wwPDB検証レポート |
|---|---|---|---|---|
| 文書・詳細版 | 5vq2_full_validation.pdf.gz | 1 MB | 表示 | |
| XML形式データ | 5vq2_validation.xml.gz | 16.8 KB | 表示 | |
| CIF形式データ | 5vq2_validation.cif.gz | 21.9 KB | 表示 | |
| アーカイブディレクトリ | https://data.pdbj.org/pub/pdb/validation_reports/vq/5vq2 ftp://data.pdbj.org/pub/pdb/validation_reports/vq/5vq2 | HTTPS FTP |
-関連構造データ
-
リンク
-
集合体
| 登録構造単位 | ![]()
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ![]()
| ||||||||||||||||||||||||||||||
| 2 | ![]()
| ||||||||||||||||||||||||||||||
| 単位格子 |
| ||||||||||||||||||||||||||||||
| 非結晶学的対称性 (NCS) | NCSドメイン:
NCSドメイン領域: Component-ID: 1 / Ens-ID: 1 / Beg auth comp-ID: HIS / Beg label comp-ID: HIS / End auth comp-ID: GLU / End label comp-ID: GLU / Refine code: 1 / Auth seq-ID: 0 - 168 / Label seq-ID: 1 - 169
NCS oper:
|
-
要素
| #1: タンパク質 | 分子量: 19393.842 Da / 分子数: 2 / 断片: residues 1-169 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 遺伝子: KRAS, KRAS2, RASK2 / 発現宿主: ![]() #2: 化合物 | #3: 化合物 | #4: 水 | ChemComp-HOH / | Has protein modification | Y | |
|---|
-実験情報
-実験
| 実験 | 手法: X線回折 / 使用した結晶の数: 1 |
|---|
-
試料調製
| 結晶 | マシュー密度: 2.71 Å3/Da / 溶媒含有率: 54.64 % |
|---|---|
| 結晶化 | 温度: 293 K / 手法: 蒸気拡散法, ハンギングドロップ法 詳細: 0.2 mol/L sodium acetate, 0.1 mol/L Tris pH 8.5, 28% PEG 3,350 |
-データ収集
| 回折 | 平均測定温度: 100 K | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 放射光源 | 由来: シンクロトロン / サイト: APS / ビームライン: 31-ID / 波長: 0.97931 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 検出器 | タイプ: RAYONIX MX225HE / 検出器: CCD / 日付: 2017年4月5日 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 放射 | プロトコル: SINGLE WAVELENGTH / 単色(M)・ラウエ(L): M / 散乱光タイプ: x-ray | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 放射波長 | 波長: 0.97931 Å / 相対比: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 反射 | 解像度: 1.96→67.91 Å / Num. obs: 29024 / % possible obs: 99.8 % / 冗長度: 5.3 % / Rpim(I) all: 0.073 / Rrim(I) all: 0.169 / Rsym value: 0.14 / Net I/av σ(I): 3.9 / Net I/σ(I): 6.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 反射 シェル | Diffraction-ID: 1
|
-
解析
| ソフトウェア |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 精密化 | 構造決定の手法: 分子置換 / 解像度: 1.96→67.91 Å / Cor.coef. Fo:Fc: 0.948 / Cor.coef. Fo:Fc free: 0.928 / SU B: 4.549 / SU ML: 0.123 / 交差検証法: THROUGHOUT / σ(F): 0 / ESU R: 0.16 / ESU R Free: 0.145 詳細: HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS U VALUES : REFINED INDIVIDUALLY
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 溶媒の処理 | イオンプローブ半径: 0.8 Å / 減衰半径: 0.8 Å / VDWプローブ半径: 1.2 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 原子変位パラメータ | Biso max: 115.29 Å2 / Biso mean: 32.908 Å2 / Biso min: 12.76 Å2
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 精密化ステップ | サイクル: final / 解像度: 1.96→67.91 Å
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 拘束条件 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Refine LS restraints NCS | 数: 1282 / タイプ: TIGHT THERMAL / Rms dev position: 1.45 Å / Weight position: 0.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LS精密化 シェル | 解像度: 1.96→2.011 Å / Rfactor Rfree error: 0 / Total num. of bins used: 20
|
ムービー
コントローラー
万見について




Homo sapiens (ヒト)
X線回折
引用


















PDBj

























